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The hepatitis C virus (HCV) induces alterations of
host cells to facilitate its life cycle. Fatty acid syn-
thase (FASN) is a multidomain enzyme that plays a
key role in the biosynthesis of fatty acids and is upre-
gulated during HCV infection. Herein, we applied ac-
tivity-based protein profiling (ABPP) that allows for
the identification of differentially active enzymes in
complex proteomic samples, to study the changes
in activity of FASN during HCV replication. For this
purpose, we used an activity-based probe based
on the FASN inhibitor Orlistat, and observed an in-
crease in the activity of FASN in the presence of a
subgenomic and a genomic HCV replicon as well as
in chimeric SCID/Alb-uPA mice infected with HCV
genotype 1a. To study the molecular basis for this in-
crease in FASN activity, we overexpressed individual
HCV proteins in Huh7 cells and observed increased
expression and activity of FASN in the presence of
core and NS4B, as measured by western blots and
ABPP, respectively. Triglyceride levels were also
elevated in accordance with FASN expression and
activity. Lastly, immunofluorescence and ABPP
imaging analyses demonstrated that while the
abundance and activity of FASN increases signifi-
cantly in the presence of HCV, its localization does
not change. Together these data suggest that the
HCV-induced production of fatty acids and neutral
lipids is provided by an increase in FASN abundance
and activity that is sufficient to allow HCV propaga-
tion without transporting FASN to the replication
complexes.
INTRODUCTION
Hepatitis C virus (HCV) is a growing health problem and currently
infects about 3% of the global population (Shepard et al., 2005).
HCV infection causes chronic liver disease, which leads to stea-
tosis, cirrhosis, and hepatocellular carcinoma (Ghany, 2009).
This virus belongs to the Flaviviridae family and its genome570 Chemistry & Biology 20, 570–582, April 18, 2013 ª2013 Elsevierconsists of a positive sense RNA that is approximately 9.6 kb
long, and encodes an 3,000 amino acid polyprotein, which is
processed into three structural proteins (core, E1, and E2) that
form the mature virion, as well as seven nonstructural proteins
(p7, NS2, NS3, NS4A, NS4B, NS5A, and NS5B), which are
involved in viral replication (Grakoui et al., 1993). Similar to other
viruses, HCV depends on the host machinery to complete its
life cycle. New methods to identify and study these complex
interactions are needed to uncover the mechanisms by which
HCV propagates and, ultimately, to develop novel strategies to
combat the infection.
HCV depends on host cell lipid biosynthesis and altered
membrane structures to efficiently replicate (Kapadia and Chis-
ari, 2005; Miyanari et al., 2007; Pezacki et al., 2010; Sagan et al.,
2006; Bassendine et al., 2011;Herker and Ott, 2011; Bugianesi
et al., 2012). Numerous genome-wide RNAi screens have re-
vealed that the host genes involved in lipid metabolism, mem-
brane biogenesis, and trafficking are crucial for HCV replication
(Li et al., 2009; Tai et al., 2009). HCV components, including
those responsible for viral particle assembly, closely associate
with lipid droplets (LD) (Boulant et al., 2007; Lyn et al., 2010).
Also, HCV has been shown to use various mechanisms to
increase the cellular lipid content, including inducing lipid
biosynthesis, impeding b-oxidation of fatty acids, and hindering
secretion of very low-density lipoproteins (VLDL) (Bassendine
et al., 2011; Mirandola et al., 2006; Perlemuter et al., 2002;
Sheikh et al., 2008; Syed et al., 2010). One of the key lipogenic
enzymes whose expression is upregulated by HCV is fatty acid
synthase (FASN; EC 2.3.1.85) (Fujino et al., 2010; Su et al.,
2002; Yang et al., 2008). Additionally, HCV infection has been
correlated with increased FASN levels in the serum of infected
patients (Aragone`s et al., 2010; Joven et al., 2011). FASN is a
270 kDa multifunctional enzyme that contains seven enzymatic
domains and harbors the complete pathway required to synthe-
size palmitic acid de novo from acetyl and malonyl esters of
coenzymeA (CoA) (Wakil, 1989). Importantly, while FASN activity
appears to be essential for HCV replication, it does not seem to
be required for adult tissuemaintenance, as long as a normal diet
is maintained (Chakravarthy et al., 2005; Lerat et al., 2009; Se-
menkovich, 1997). Thus, FASN is an important host enzyme
whose expression is altered by HCV, but HCV’s influence on
FASN enzyme activity and localization is not well established.
FASN enzyme activity is important in establishing infection of
other RNA viruses through the creation of altered membraneLtd All rights reserved
Chemistry & Biology
HCV-Induced Fatty Acid Synthase Enzyme Activitystructures. De novo lipid biosynthesis and incorporation of newly
synthesized lipids at sites of viral replication are necessary for
the replication of other members of the Flaviviridae family
including Dengue virus (DENV), yellow fever virus (YFV), Usutu
virus (USUV), and West Nile virus (WNV). Inhibition of FASN by
small molecule inhibitors such as Cerulenin, Orlistat, and C75
leads to a drastic inhibition of viral replication (Heaton et al.,
2010; Kapadia and Chisari, 2005; Martı´n-Acebes et al., 2011;
Miyanari et al., 2007; Perera et al., 2012; Sagan et al., 2006; Su
et al., 2002). Interestingly, while the levels of FASN expression
do not change significantly during DENV and WNV infection, its
subcellular localization changes from the cytosol to being prox-
imal to the sites of viral replication, so that nascent fatty acids
can be utilized to establish or expand replication complexes
(Heaton et al., 2010; Martı´n-Acebes et al., 2011; Perera et al.,
2012). However, it is not known whether HCV modifies FASN
localization and activity in a similar fashion. Transcriptional acti-
vation of lipogenic enzymes, such as FASN and acetyl-CoA
carboxylase (ACC), have been demonstrated during the HCV
replication (Waris et al., 2007). To date, however, it is not known
whether these enzymes are catalytically active or if HCV recruits
these enzymes to the vicinity of the HCV replication complexes.
FASN enzyme activity requires posttranslational activation. To
be catalytically competent, the central acyl carrier domain (ACP)
of FASN must be posttranslationally modified by an intrinsic
phosphopantetheine transferase (PPT) that covalently attaches
the phosphopantetheine moiety of coenzyme A (CoA) onto a
conserved serine residue of the ACP (Johansson et al., 2009;
Pemble et al., 2007; Schweizer and Hofmann, 2004). Also, bio-
tinylation is indispensable for the activity of ACC (Pacheco-
Alvarez et al., 2004). Traditional abundance-based approaches
fail to report on the functional state of FASN and other enzymes.
Therefore, novel experimental approaches are required to inter-
rogate the catalytic state of lipogenic enzymes involved in HCV
infection, and provide an in-depth analysis of the dynamic and
transient interactions that affect the enzymatic function of host
factors during viral replication.
Activity-based protein profiling (ABPP) was developed as a
functional proteomics tool to report on the catalytic states of
enzyme classes in native biological systems, assign function to
proteins with unknown function, and provide insight into en-
zymes mechanisms (Barglow and Cravatt, 2007; Cravatt et al.,
2008). In this strategy, small molecule inhibitors, which are
conjugated to reporter or affinity tags, are exploited to target
the catalytic active sites of different enzyme classes (Barglow
and Cravatt, 2007; Cravatt et al., 2008; Martin et al., 2011).
Labeled proteins are then purified and subsequently identified
by mass spectrometry. ABPP has been successfully used to
interrogate host-pathogen interactions and led to the discovery
of novel host factors involved in viral pathogenesis (Blais et al.,
2012; Marnett et al., 2004; Ovaa et al., 2004; Role´n et al.,
2006). Furthermore, by applying several mechanistically-
different ABPs, our group has identified numerous enzymes
encompassing many enzyme families that are differentially
active during HCV replication (Blais et al., 2010a, 2010b; Singar-
avelu et al., 2010). Given the significance of the lipogenic en-
zymes in the replication cycle of HCV, we were interested in
examining the possible modulation of the activity of FASN by
this virus. In this study, we used an ABP based on Orlistat, aChemistry & Biology 20,US Food and Drug Administration (FDA)-approved drug (Padwal
and Majumdar, 2007) and known inhibitor of FASN to investigate
the HCV-induced alterations in the activity of FASN (Yang et al.,
2010, 2011, 2012.). Herein, we find an increase in the expression
and activity of FASN in the presence of HCV. We also observed
that FASN activity is increased during overexpression of
individual HCV proteins, such as core and NS4B, which leads
to accumulation of triglyceride in the hepatic cells. Furthermore,
we investigated the possible change in the localization of both
total FASN and active FASN in the presence of HCV replicon
and observed that while the abundance of both total and active
FASNmarkedly increases during HCV replication, its localization
does not change in contrast to what has been reported in DENV
and WNV.
RESULTS
Protein Profiling Using Orlistat-Based Probes
Orlistat, or tetrahydrolipstatin (THL), is an FDA-approved drug
against obesity (Ballinger and Peikin, 2002; Henness and Perry,
2006) that makes a covalent bond, through its b-lactone moiety,
to the nucleophilic serine (Ser2308) in the active site of the thio-
esterase (TE) domain of FASN (Figure S1A available online)
(Pemble et al., 2007). Orlistat is cell permeable (Knowles et al.,
2004) and therefore makes a promising activity-based probe
that can be applied both in situ and in vitro to report on the activ-
ity of its targets in the subcellular environment and homogenized
cells or tissues, respectively. Moreover, minor structural modifi-
cations of Orlistat, such as introducing an alkyne handle, can be
performedwithout having a drastic effect on its biological activity
(Richardson et al., 2008; Yang et al., 2010). As a result, conser-
vative structural changes have been performed to the parental
THL structure to convert Orlistat into a competent activity-based
probe (Richardson et al., 2008; Yang et al., 2011). In addition, an
alkyne handle has been introduced to the THL structure, which
allows for conjugation of the protein/probe complex to reporter
and affinity tags via bio-orthogonal click chemistry (Evans and
Cravatt, 2006; Yang et al., 2010).
First, a library of seven Orlistat-based probes (Figure S1B),
which has already been applied to target FASN in HepG2 cells
(Yang et al., 2011), was screened for its specificity against
FASN in Huh7 cells. For this purpose, in situ (data not shown)
and in vitro (Figure S1C) labeling was carried out and the reaction
products were separated by SDS-PAGE and visualized in-gel
using a flatbed fluorescence scanner. As demonstrated, the Orli-
stat analog probes 1 to 5 all labeled FASN whereas analogs 6
and 7 did not label FASN appreciably. We chose probe 2 (Fig-
ure 1A) for further experiments because it shows a strong spe-
cific activity-based labeling toward its FASN target. Overall,
these results demonstrate that the Orlistat-based probe can
function as an activity-based probe in Huh7 human hepatoma
cells to report on the activity of FASN.
Next, the specificity of the Orlistat-based probe 2 (Figure 1A)
toward FASN was further evaluated by performing competitive
ABPP, in which prior to labeling with the corresponding probe,
the proteome is incubated with an excess of different inhibitors,
some of which compete for the same active site that the probe
targets (Li et al., 2007). For this purpose, the proteome was pre-
incubated with known FASN inhibitors, such as Cerulenin and570–582, April 18, 2013 ª2013 Elsevier Ltd All rights reserved 571
Figure 1. The Orlistat-Based Probe Is Specific for the TE Domain of FASN
(A) The structures of Orlistat and the Orlistat-based probe with alkyne moiety highlighted.
(B) Fresh proteome isolated from Huh7 is incubated with 100 mM of inhibitors for 1 hr followed by labeling with 10 mM of Orlistat-based probe. D is the heat-
denatured sample.
(C) The percentage activity remaining was determined by measuring the IOD of the FASN band relative to a DMSO-only (no inhibitor) control normalized to a
loading control (PTP-1D). The data represent the average of three independent gels. Error bars are SD.
Also see Figure S1.
Chemistry & Biology
HCV-Induced Fatty Acid Synthase Enzyme ActivityC75, which irreversibly inactivate the b-ketoacyl-ACP synthase
domain but not the thioesterase domain of FASN (Moche et al.,
1999; Pappenberger et al., 2010), as well as 5-(tetradecyloxy)-
2-furoic acid (TOFA), an established inhibitor of ACC (Halvorson
andMcCune, 1984), the enzyme that catalyzes the production of
malonyl-CoA, which is subsequently used as a substrate by
FASN. As expected, in the presence of excessive amounts of
Orlistat inhibitor, the Orlistat-based probe is outcompeted
and cannot label the thioesterase domain of FASN (Figure 1B,
lane 3); however, neither C75 nor Cerulenin abolishes the label-
ing of the Orlistat-based probe toward FASN (Figure 1B, lanes572 Chemistry & Biology 20, 570–582, April 18, 2013 ª2013 Elsevier4-5), which indicates that the labeling is both target- and
domain-specific. This shows that the probe can also be used
to distinguish between different domains of FASN. The percent-
age activity remaining was determined by measuring the inte-
grated optical density (IOD) of the FASN band relative to a
DMSO-only (no inhibitor) control (Tsuboi et al., 2010), normalized
to a loading control (PTP-1D) (Figure 1C). Moreover, the heat-
denatured proteome (D; first lane) did not show any labeling
with Orlistat ABP, which further validates that the probe only
targets the active enzyme. Collectively, these data show
that the Orlistat-based probe has high specificity toward theLtd All rights reserved
Figure 2. FASN Activity Increases during
HCV Replication
(A) Schematic representations of the HCV re-
plicons used in this study.
(B) Huh7 cells that stably express a tricistronic
HCV replicon containing the firefly luciferase re-
porter gene were treated with the inhibitors of fatty
acid synthesis at 10 mM for 48 hr, and the HCV
replication was examined as a measure of lucif-
erase activity compared to DMSO treatment. The
results were normalized against total protein levels
and are demonstrated as the average of three in-
dependent experiments and the error bars are SD.
(C) Huh7 cells expressing or not the Con1 full-
length replicon (HCV), were lysed and probed
against active FASN (ABPP-FASN), total FASN
(anti-FASN), and PTP-1D (anti-PTP-1D). A repre-
sentative gel is shown in which the activity and
expression of FASN was examined in Huh7 cells
harboring full-length HCV replicon genotype 1b.
(D) Comparison of the activity and expression of
FASN in Huh7 cells harboring the full-length HCV
replicon with mock control. The data represent the
average of four independent gels. P value = 0.005
and 0.008 for activity and expression, respec-
tively, calculated by two-tailed Student’s t test.
(E) Comparison of the activity and expression of
FASN in chimeric mice infected with genotype 1a
to uninfected control chimeric mice. A represen-
tative gel is shown.
(F) Quantification of signal intensity for the band
corresponding to FASN was followed by back-
ground correction. The results are shown as
normalized FASN activity of infected relative to
uninfected chimeric mice. The data represent the
average of four independent gels. P value = 0.01,
calculated by two-tailed Student’s t test.
Also see Figure S2.
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alkyne handle does not change its preference in enzyme selec-
tivity in Huh7 cells.
The Expression and Activity of FASN Increases during
HCV Infection
Previous reports have demonstrated that de novo fatty acid
synthesis is required for HCV replication (Kapadia and Chis-Chemistry & Biology 20, 570–582, April 18, 2013ari, 2005; Su et al., 2002), and HCV infec-
tion is associated with the accumulation
of lipid in hepatocytes (i.e., steatosis).
To further confirm the role of FASN activ-
ity in HCV replication, we used inhibitors
of fatty acid synthesis to Huh7 cells that
stably express a tricistronic HCV sub-
genomic replicon, with firefly luciferase
reporter gene (Figure 2A). At 48 hr post-
treatment, the luciferase activity was
examined as a measure of HCV replica-
tion. As shown in Figures 2B and 2C, in
the presence of Orlisat, Cerulenin, and
TOFA, HCV replication decreases by
50%, 70%, and 65%, respectively,compared with DMSO treatment. This is consistent with the inte-
gral role of fatty acid synthesis in HCV replication.
Moreover, in situ studies have demonstrated that FASN
expression increases during HCV replication (Su et al., 2002;
Yang et al., 2008). To examine whether the activity of FASN is
also elevated by the HCV replication, we applied comparative
ABPP (Cravatt et al., 2008), which compares the differential
activity between healthy and virus-infected host proteomes.ª2013 Elsevier Ltd All rights reserved 573
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HCV-Induced Fatty Acid Synthase Enzyme ActivityOrlistat-based ABP (Figure 1A) was used to profile the activity of
FASN in Huh7.5 cells harboring a full-length genotype 1b HCV
genomic replicon (FGR) (Figure 2A). The activity was determined
by measuring the IOD of the band corresponding to FASN in the
fluorescent gel, normalized to IOD of the band corresponding to
a loading control (PTP-1D) in the respective western blot. In both
in vitro and in situ labeling experiments, FASN activity increased
by approximately 75% in the presence of HCV replicon, while
FASN expression, determined by IOD of the FASN band in the
western blot normalized to the loading control, increased by
45% (Figures 2C and 2D).
To further investigate the role of FASN in the HCV life cycle, we
used an established mouse model for HCV infection in which
primary human hepatocytes are transplanted into SCID mice
carrying a plasminogen activator transgene (Alb-uPA). This
model has been shown to support HCV infection without
inducing an adaptive immune response (Mercer et al., 2001). In
this chimeric mouse model, HCV replication occurs at biologi-
cally relevant levels, and infectious viral particles are produced
and released (Mercer et al., 2001; Walters et al., 2006). We con-
ducted ABPP experiments in chimeric SCID/Alb-uPA mice in-
fected with HCV genotype 1a, which are more reflective of
patient infections. Orlistat-based ABPwas used on liver samples
obtained from three chimeric mice that were infected with HCV
genotype 1a and maintained the HCV infection for 10 weeks
with serum titers between 2 3 105 and 4 3 107 copies/ml.
FASN activity was compared with the liver samples from three
uninfected SCID mice harboring human primary hepatocytes
(matched donors). As depicted in Figures 2E and 2F, HCV in-
duces a 50% increase in the activity of FASN in the chimeric
livers, with a p value of 0.01calculated by a two-tailed Student’s
t test. Moreover, this increase in the activity of FASN in the liver of
infected chimeric mice is in agreement with its total abundance
(Figure S2). These findings provide additional evidence that
FASN activity assists HCV replication and therefore its expres-
sion and activity is increased by the virus.
Modulation of the Activity and Expression of FASN
by HCV-Encoded Proteins
FASN expression is primarily regulated at the transcriptional
level by sterol response element-binding protein-1c (SREBP-
1c) (Horton et al., 2002) and some of the HCV structural and
nonstructural proteins, including core (Jackel-Cram et al.,
2007; Kim et al., 2007), NS2 (Oem et al., 2008), NS4B (Park
et al., 2009), and NS5A (Garcı´a-Mediavilla et al., 2012; Xiang
et al., 2010), have been demonstrated to activate the SREBP-
1c transcriptional pathway, which can lead to increased tran-
scription of lipogenic enzymes such as FASN. Moreover, studies
have shown that the HCV proteins core and NS5A can activate
the phosophoinositide-3 kinase (PI3K)-AKT pathway, which in
turn leads to the activation of the SREBP-1 pathway (Jackel-
Cram et al., 2010; Street et al., 2005). To study whether the acti-
vation of SREBP-1c pathway results in an increase in abundance
of active FASN, we examined the alterations in the activity and
expression of FASN in the presence of individual HCV proteins.
For this purpose, we cloned and expressed the HCV proteins
that have been shown to activate the SREBP-1c pathway in
Huh7 cells, including E1/E2, core, NS2, NS4B, and NS5A.
Forty-eight hours after transfection, cell lysate from each trans-574 Chemistry & Biology 20, 570–582, April 18, 2013 ª2013 Elsevierfection was first analyzed by western blotting to ensure transfec-
tion success (data not shown), and subsequently the activity and
expression of FASN was examined as mentioned before. The
activity of FASN was significantly induced by NS4B, core, and
NS5A, with 1.75-, 1.5-, and 1.4-fold increase compared to
mock, respectively; while E1/E2 and NS2 do not seem to have
a drastic effect on the activity and expression of FASN (p value >
0.05) (Figures 3A and 3B). The increase in the activity of FASN in
the activity of FASN is in accordance with an increase in the
abundance of total FASN (Figure S3).
Increased FASN Activity Reflects in the Cellular
Triglyceride Levels
The main product of FASN is the 16-carbon saturated fatty acid
palmitate, which can be processed to be incorporated into tri-
glycerides (Listenberger et al., 2003). Therefore, to further study
the changes in FASN activity induced by HCV and its proteins,
we quantified the amount of cellular triglyceride (TG) levels as
an indirect measurement of FASN activity. For this purpose,
we analyzed cellular TG levels in Huh7 cells that stably express
full-length HCV replicon (Huh7-FGR) or those transiently trans-
fected with individual HCV proteins, or mock transfected Huh7
cells. As shown in Figure 4, while NS4B, core, NS5A, and HCV
replicon increased the total cellular TG content significantly,
E1/E2 and NS2 did not cause a significant increase in cellular
TG levels. Thus, we concluded that increased activity of FASN
in the presence of HCV replicon, core, NS5A, and NS4B corre-
late with higher cellular TG levels.
The Localization of FASN Does Not Change during
HCV Replication
Two of the HCV-encoded proteins, core and NS4B, are palmi-
toylated at the cysteine residues of their C-terminal ends, and
this palmitoylation is essential for the replication of the virus
(Majeau et al., 2009; Yu et al., 2006). Palmitic acid produced
by FASN can be subsequently used by palmitoyltransferase
(PAT) for palmitoylation of certain cysteine residues (Dietrich
and Ungermann, 2004). It is possible that HCV requires FASN
activity to palmitoylate core and NS4B. Furthermore, studies
have shown that the distribution of FASN changes to colocalize
with replication sites during infections with DENV, USUV, and
WNV, which also belong to the Flaviviridae family, and require
fatty acid synthesis for their replication (Heaton et al., 2010; Per-
era et al., 2012). Therefore we decided to investigate whether the
subcellular localization of FASN similarly changes during HCV
replication to the vicinity of replication complexes in membra-
nous webs or LD, where NS4B and core also localize (Barba
et al., 1997; Elazar et al., 2004). For this purpose, Huh7 cells ex-
pressing or not expressing the HCV subgenomic replicon (SGR)
(genotype 1b, Figure 2A) were immunostained with antibodies
against FASN and HCV NS5A (Figure 5A), which associates
with HCV replication complex (RC) (Gosert et al., 2003), and
dsRNA (Figure 5B), the HCV replication intermediate. The cells
were subsequently analyzed by fluorescence microscopy and
the image analyses revealed that the distribution and localization
of FASN, which is mainly perinuclear, does not change in the
presence or absence of the HCV replicon (Figures 5A and 5B).
To investigate the possibility of colocalization between total
FASN and NS5A, or dsRNA, we calculated the degree ofLtd All rights reserved
Figure 3. Investigating the Effect of Individual HCV Proteins on FASN Expression and Activity
(A) Huh7 cells transfected with individual HCV genes, or expressing Con1 full-length replicon (HCV), were lysed and probed against active FASN (ABPP-FASN),
total FASN (anti-FASN), and PTP-1D (anti-PTP-1D). A representative gel is shown demonstrating the alterations in the activity and expression of FASN in the
presence of different HCV proteins.
(B) Densitometry analysis of the bands corresponding to FASN on ABPP gels was performed by ImageJ, and the data were normalized to the loading control
(PTP-1D) on corresponding western blots. The results are demonstrated as fold changes compared to mock and represent the mean from four gels of inde-
pendent transfections. The error bars are SD. *p < 0.05, **p < 0.01, calculated by two-tailed Student’s t test.
Also see Figure S3.
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HCV-Induced Fatty Acid Synthase Enzyme Activitycolocalization by measuring Mander’s coefficient (R) and Pear-
son correlation coefficient (Rr). Mander’s coefficient indicates
an actual overlap of the signals and provides an estimation of
the percentage of overlapped pixels. Its values vary from 0 to 1
(0 = nonoverlapping images and 1 = colocalized images); impor-
tantly, it strictly measures co-occurrence independent of signal
proportionality (Dunn et al., 2011; Manders et al., 1993). We
also calculated the colocalization using the Pearson correlation
coefficient, which measures the pixel-by-pixel covariance in
the signal levels of two images, and describes the correlation
of the intensity distribution between channels. The range for
Pearson correlation coefficient is from 1 to 1 (1 = total nega-
tive correlation, 0 = random correlation, and 1 = total positiveChemistry & Biology 20,correlation) (Adler and Parmryd, 2010; Zinchuk and Grossen-
bacher-Zinchuk, 2011). TheMander’s coefficient for overlapping
signals between total FASN and NS5A, or dsRNA is 0.95 ± 0.03,
and 0.93 ± 0.03, respectively. However, the Pearson correlation
coefficient is only 0.53 ± 0.11 and 0.42 ± 0.09 for FASN and
NS5A, or dsRNA, respectively. Therefore these data suggest
that although there is some overlap between total FASN and
NS5A, or dsRNA, there is a moderate or low correlation between
their signal intensities, which is indicative of minimal molecular
interaction between FASN and the HCV RC.
Next we set to examine the distribution of active FASN during
HCV replication, by combining ABPP imaging with immunofluo-
rescence microscopy. For this purpose, we first validated the570–582, April 18, 2013 ª2013 Elsevier Ltd All rights reserved 575
Figure 4. Total Amount of Cellular Triglyc-
eride in the Presence of either the HCV
Replicon, or of Individual HCV Proteins
Huh7 cells transfected with individual HCV genes
or expressing Con1 full-length HCV replicon were
lysed and the total amount of triglyceride was
measured. The results of triglyceride assays were
normalized to total protein content and demon-
strated as nanomol per milligram of protein. The
data represent the mean of three independent
assays. The error bars are SD.*p < 0.05, **p < 0.01,
calculated by two-tailed Student’s t test.
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and Huh7-SGR cells with the Orlisat-based probe, followed by
conjugation to rhodamine azide through click chemistry and
immunostaining against total FASN. As shown in Figure 6A,
ABPP-labeled FASN evidently colocalizes with total antibody-
labeled FASN and shows a similar perinuclear pattern in both
mock Huh7 cells and Huh7-SGR. The calculated Mander’s and
Pearson coefficients for the colocalization of total FASN and
ABPP-FASN, in the presence of the HCV subgenomic replicon,
are 0.97 ± 0.03, and 0.93 ± 0.03, respectively, and in naive
Huh7 cells are 0.99 ± 0.01 and 0.94 ± 0.02, which indicate that
active FASN highly colocalizes with total FASN in the presence
or absence of the HCV subgenomic replicon. Importantly,
minimal fluorescence was observed in Huh7 cells and Huh7-
SGR cells treated with the click mix only in the absence of the
Orlistat probe (Figure S4). There is also a considerable increase
in the levels of active FASN detected in the presence of the
HCV subgenomic replicon, which is consistent with previously
shown data.
Subsequently, we examined the possible relocalization of
active FASN to the proximity of HCV RC by probing against
active FASN and NS5A (Figure 6B; Figure S5A) or dsRNA (Fig-
ure 6C; Figure S5B). As demonstrated, there is no apparent
colocalization between active FASN and sites of active viral repli-
cation. Mander’s and Pearson coefficients for ABPP-FASN and
NS5A are 0.97 ± 0.01 and 0.61 ± 0.18, respectively, and for
ABPP-FASN and dsRNA are 0.97 ± 0.015 and 0.63 ± 0.08. These
results indicate that the overlap between signals from active
FASN andNS5A or dsRNAdo not represent a true colocalization,
and can be explained by the drastic increase in the levels of
FASN throughout the cytoplasm during HCV replication, which
leads to a coincidental overlap between HCV RC that are also
localize in the cytoplasm. Based on these results, we propose
that the drastic increase in the activity and abundance of FASN
during HCV replication leads to production of substantial
amounts of fatty acids, and therefore HCV does not require the
recruitment of FASN to the sites of active viral replication.
DISCUSSION
FASN abundance and de novo fatty acid synthesis are frequently
deregulated in a wide range of human cancers, metabolic dis-576 Chemistry & Biology 20, 570–582, April 18, 2013 ª2013 Elsevier Ltd All rights reservedeases, and viral infections (Menendez
and Lupu, 2007; Menendez et al., 2009;
Nguyen et al., 2010), indicating the impor-tance of targeting this enzyme for therapeutic purposes. While
previous studies have demonstrated that FASN is indispensible
for HCV replication and also that FASN abundance increases
during HCV replication (Fukasawa et al., 2006; Oem et al.,
2008; Su et al., 2002; Yang et al., 2008), changes in FASN enzy-
matic activity and localization related to HCV propagation are not
well understood. Herein we present the changes in enzymatic
activity of FASN during HCV replication using activity-based pro-
tein profiling and activity-based imaging techniques.
Orlistat inhibits the activity of FASN by making an irreversible
covalent bond to the active serine of the carboxy-terminal thio-
esterase (TE) domain of FASN (Zhanget al., 2011). TheTEdomain
is important because it determines the length of the fatty acyl
chain by controlling its release from the enzyme complex (Zhang
et al., 2011). Therefore the TE domain plays a critical role in the
terminal end of fatty acid biosynthesis, and using an ABPP probe
to report on its catalytic activity would provide insight into the
overall activity of FASN. Consequently we utilized Orlistat-based
probes that were designed to specifically report on the functional
state of FASN (Yang et al., 2010, 2012) to investigate the alter-
ations in the activity of FASN during HCV replication.
Our results from ABPP studies both in cells expressing HCV
proteins and in model systems for HCV propagation confirm
the previous findings that HCV infection upregulates FASN
expression at both transcriptional and protein levels and also
demonstrate that the increase in FASN abundance during HCV
replication leads to an increase in the overall FASN catalytic ac-
tivity (Figure 2). Importantly, the effect of HCV replication on the
expression and activity of FASN was observed in both cell
models harboring genotype 1b replicon as well as chimeric
SCID/Alb-uPA mice containing human hepatocytes infected
with HCV genotype 1a, which demonstrates that the modulation
of FASN by HCV occurs in different model systems and appears
to occur with different subtypes of HCV. Moreover, our results
show that elevated FASN activity during HCV replication leads
to an increase in cellular TG content, although the FASN activity
and cellular TG levels are more highly correlated in the case of
core and NS4B as compared with NS5A. This inconsistency
can be explained by the fact that other than becoming TG and
incorporated into LDs, the nascent fatty acids synthesized by
increased expression and activity of FASN can have different
fates, such as incorporation into membranes and as substrates
Figure 5. FASN Does Not Colocalize with the HCV RC
Huh7 cells and Huh7 cells harboring subgenomic HCV replicon (Huh7-SGR) were fixed and probed against total FASN (a-FASN) and (A) HCV NS5A (a-NS5A) or
(B) dsRNA (a-dsRNA), the HCV replication intermediate, followed by DAPI staining. Scale bar: 10 mm. The images are representative of four independent im-
munostaining experiments.
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protein targets. For example NS5A expression has been shown
to activate phosophatydilinositol 3 kinase (PI3K) and PI4K (Street
et al., 2005; Vaillancourt et al., 2012), which in turn induce the
synthesis of phosphoinositide 3 and 4 phosphate, respectively.
These phosphoinositides are essential for the formation and
integrity of endoplasmic reticulum (ER) as well as the HCV-
induced membranous web (Street et al., 2005; Vaillancourt
et al., 2012).
Previous reports have demonstrated that expression of NS4B
alone induces the formation of membranous webs (Gouttenoire
et al., 2010; Liefhebber et al., 2009), which are specific alter-
ations in the ER membrane that harbor HCV RC. Additionally, it
has been shown that NS4B expression activates the SREBP1
pathway that can lead to increased transcription of FASN (Ballin-
ger and Peikin, 2002). We observed a robust increase in both
FASN activity and TG levels in the presence of NS4B (Figures
3 and 4), which may reflect the need for lipid components for
HCV to induce membrane rearrangements. The expression of
core protein has also been associated with increased cellular
LD and activation of SREBP1 pathway. Consistent with this,
our results demonstrated that core protein induces a significantChemistry & Biology 20,increase in both FASN activity and TG levels. The involvement of
NS4B and core in the induction of lipid biosynthesis and
accumulation of lipid in hepatocytes may also contribute to the
pathogenesis of liver steatosis in patients with chronic hepatitis
C (Syed et al., 2010). Interestingly, we observed higher levels
of activity compared to the abundance of FASN in the presence
of HCV. This could possibly be due to an influence of HCV on the
posttranslational modifications of FASN that ultimately regulate
its conformation and enzymatic activity. Future works will be
directed toward understanding the role of HCV replication and
its encoded proteins on posttranslational modifications of
FASN and other lipogenic enzymes in the liver.
Recent reports have shown that FASN activity is required for
other members of Flaviviridae, including DENV, WNV, and
USUV (Heaton et al., 2010; Martı´n-Acebes et al., 2011; Perera
et al., 2012). Interestingly, during the replication of these viruses,
the level of FASN abundance does not change; however, its
distribution changes to colocalize with RC. In fact, Randall and
coworkers demonstrated that the NS3 protein of DENV interacts
with FASN and recruits it to the RC (Heaton et al., 2010). There-
fore, we investigated the possible colocalization of FASN with
HCV replication sites by confocal microscopy. Our imaging570–582, April 18, 2013 ª2013 Elsevier Ltd All rights reserved 577
Figure 6. Active FASN Is Not Recruited to Sites of HCV Replication
(A) Huh7 cells and Huh7 cells harboring subgenomic HCV replicon (Huh7-SGR) were treated with Orlistat-based probe fixed and clicked with Rhodamine azide
(ABPP-FASN), followed by immunostaing against total FASN (a-FASN).
(B and C) Huh7 cells harboring subgenomic HCV replicon were probed against active FASN (ABPP-FASN) and HCV NS5A (a-NS5A) or (C) dsRNA (a-dsRNA).
Scale bar: 10 mm. The images are representative of four independent immunostaining experiments.
Also see Figures S4 and S5.
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replication. However, in contrast to DENV, our imaging experi-
ments show that FASN is not recruited to the HCV RC, because
its localization remains similar in the absence or presence of
the HCV replicon. More in-depth analysis of colocalization using
image analysismethodologies helped us to address the question
of HCV recruitment of FASN to replication sites.
The analysis of colocalization between FASN and NS5A or
dsRNA, by calculating Mander’s coefficient, revealed that there
is some overlap between the signals, but because the Pearson
coefficient, which is considered to be better than Mander’s
coefficient in quantifying colocalization (Adler and Parmryd,
2010), is moderate for both sets of studies, it can be concluded
that the overlap between FASN and NS5A or dsRNA is likely to
be coincidental (Figure 5). Interestingly, a parallel study by
Huang and coworkers reported that HCV NS5B interacts with578 Chemistry & Biology 20, 570–582, April 18, 2013 ª2013 ElsevierFASN, as deduced by immunoprecipitation, and this interaction
appears to increase the RNA-dependent RNA polymerase
(RdRp) activity (Huang et al., 2013). Herein we detected only a
partial colocalization of FASN with HCV RC, which could still
interact with NS5B, and enhance its RdRp activity. However,
our study suggests that any interaction of NS5B (or other HCV
proteins) with FASN is not sufficient to drastically alter FASN
localization within the cell.
Next we analyzed whether HCV alters the distribution of active
FASN, using ABPP imaging to visualize the localization of active
FASN during HCV replication. Our results demonstrate that the
ABPP-labeled FASN highly colocalizes with the antibody-
labeled FASN, which confirms the specificity of ABPP imaging
(Figure 6). Colocalization analyses based on the Pearson coeffi-
cients (Adler and Parmryd, 2010) indicate that there is no signif-
icant colocalization between active FASN and either NS5A orLtd All rights reserved
Chemistry & Biology
HCV-Induced Fatty Acid Synthase Enzyme ActivitydsRNA. Colocalization studies also confirm that active FASN is
not recruited to the sites of HCV replication. However, the level
of active FASN is considerably increased in Huh7-SGR cells
and therefore there is some overlap between the signals from
active FASN and NS5A or dsRNA, but these signals are not
completely codependent. Consequently, we propose that the in-
creases in FASN abundance and activity during HCV replication
provides ample amounts of fatty acids and neutral lipids required
for proper replication of the virus, and therefore there is no need
for direct interaction and colocalization of FASN with the RC.
In summary, we demonstrated the application of ABPP to
study the HCV-induced changes in the enzymatic activity of
FASN. We showed that FASN expression is not only robustly
induced during HCV replication, but this is commensurate with
a significant increase in FASN catalytic activity. We also demon-
strated that individual proteins such as core and NS4B are suffi-
cient to induce FASN activity on their own and this increase in
activity is correlated with increases in triglyceride neutral lipid
products. Finally, fluorescence microscopy analyses show that
colocalization of FASN with the RC is not required for HCV prop-
agation, unlike other flaviviruses. These results also highlight the
potential of activity profiles of enzymes such as FASN as prog-
nostic markers of HCV infection.
EXPERIMENTAL PROCEDURES
Cell Culture
Human hepatoma cells (Huh7) were cultured in Dulbecco’s modified Eagle’s
medium (DMEM, Invitrogen, Burlington, ON, Canada) supplemented with
100 nM nonessential amino acids, 50 U/ml penicillin, 50 mg/ml streptomycin,
and 10% fetal bovine serum (FBS, PAA Laboratories, Etobicoke, ON, Canada).
The hepatoma cells stably expressing the HCV full-length replicon (genotype
1b, con1), a kind gift from Dr. Charles Rice (Rockefeller University, USA),
were maintained in the same culture medium supplemented with 250 mg/ml
G418 Geneticin (GIBCO-BRL, Burlington, ON). The pFK-I389neo/NS3-30/5.1
subgenomic replicon was kindly provided by Dr. Ralf Bartenschlager (Institute
of Hygiene, University of Heidelberg, Germany).
Inhibitor Treatments
Huh7 cells that stably expressing HCV replicons were seeded in a six-well
plate. After 24 hr, at a confluency of 80%, cells were treated with Orlistat, Cer-
ulenin, C75, and TOFA all purchased fromCayman Chemicals (Michigan, USA)
at 10 mM final concentration for 48 hr at 37C. At this time point, cells were
washed once with PBS and lysed with cell culture lysis buffer (Promega,
Madison, WI). Luciferase assay substrate was added and the luminescence
was measured with an Lmax luminometer (Molecular Devices Corporation,
Sunnyvale, CA). Values were normalized against total protein content using
the Bio-Rad DC Protein Assay (Bio-Rad, Mississauga, ON) according to the
manufacturer’s protocol.
Active Proteome Extraction for Labeling
Subconfluent cells were washed and pooled with ice-cold PBS pH 7. The
chimeric liver tissues were subjected to Dounce homogenization at 50%
power (T8 Ika-Werke Homogenizer, GMBH [Staufen, Germany]). The lysates
were then sonicated (10 pulses, 50% duty cycle; Sonifier 250, Branson Ultra-
sonic [Danbury, CT]) in ice-cold PBS supplemented with 1% Triton X-100. The
protein extract was quantified with the DC protein assay (BioRad), and diluted
with sodium phosphate buffer to a final protein concentration of 1 mg/ml.
In Vitro and In Situ Proteome Labeling and Analysis
For in vitro proteome labeling, probes were added to cell lysates (50 mg) in 50 ml
of PBS at a final concentration of 10 mM in the presence or absence of
excess Orlistat, C75, or Cerulenin competitor (a final concentration of
100 mM). Unless indicated otherwise, samples were incubated for 1 hr atChemistry & Biology 20,room temperature. After incubation, 100 ml of the freshly premixed click
chemistry reaction cocktail in PBS (rhodamine azide [200 mM, 100 mM stock
solution in DMSO], tris(2-carboxyethyl)phosphine hydrochloride [TCEP;
2 mM, 50 mM freshly prepared stock solution in deionized water], tris[(1-
benzyl-1H-1,2,3-triazol-4-yl)methyl] amine [TBTA; 200 mM, 50 mM stock solu-
tion in DMSO], and CuSO4 [2 mM, 50 mM freshly prepared stock solution in
deionized water]) was added and vortexed, then incubated for 2 hr at room
temperature with gentle mixing. The reactions were terminated by the addition
of prechilled acetone (1 ml), placed at 80C for 15 min and centrifuged at
14,000 rpm for 15 min at 4C to precipitate proteins. The protein pellets
were allowed to air-dry for 10min, resuspended in 25 ml 13 standard reducing
SDS-loading buffer, heated for 10 min at 95C; and separated by 10%
SDS-PAGE, then visualized by in-gel fluorescence scanning using the FMBIO
Fluorescence Scanner (Hitachi).
For in situ labeling, Huh7 cells were grown to 80%–90% confluence in six-
well plates under the conditions described previously. The medium was
removed, and then cells were washed with PBS, and treated with 0.5 ml of
DMEM-containing probe (20 mM), with or without Orlistat, C75, TOFA, or
Cerulenin (200 mM). Probes were applied from DMSO stocks, while DMSO
never exceeded 1% in the final solution. The same volume of DMSO was
used as a negative control. After 2 hr of incubation at 37C/5% CO2, the
medium was aspirated, and cells were washed with PBS to remove the exces-
sive probe, and lysed with 200 ml PBS containing 1% Triton. The lysate was
then homogenized by sonication, and diluted to 1 mg/ml with PBS. Probe
targets were detected by click chemistry with rhodamine azide, SDS-PAGE
analysis, and in-gel fluorescence scanning.
Western Immunobloting
Subsequent to in-gel fluorescence scanning, the proteome is transferred onto
Hybond-P PVDF membrane (Amersham Biosciences). Thereafter, the mem-
brane was blocked for 1 hr in 3% dried skim milk in Tris-buffered saline (TBS)
with 0.05% Tween-20. Human FASN and protein tyrosine phosphatase 1D
(PTP-1D, as the loading control), HCV core, E1/E2, NS2, NS4B, and NS5A,
were targeted with a mouse monoclonal anti-FASN (2,000-fold dilution; Santa
Cruz Biotechnology), a mouse monoclonal anti-PTD1B (10,000-fold dilution;
BD Laboratories), a mouse monoclonal anti-HCV core (2,000-fold dilutions
Abcam), a goat monoclonal anti-HCV E1 (1:2,000, Virostat), a mouse mono-
clonal anti-FLAG (2,000-fold dilutions, SIGMA), a mouse monoclonal anti-
HCV NS4B (2,000-fold dilutions, Abcam), and a mouse monoclonal anti-NS5A
(2,000-fold dilution; ViroStat), respectively. Bound primary antibody was de-
tected with HRP-conjugated anti-mouse antibody, and the blots were devel-
oped using a chemoluminescent detection system (ECL prime, Amersham).
Measurement of Cellular Triglyceride Levels
At 48 hr posttransfection, lipids were extracted from 106 trypsinized cells. Tri-
glyceride levels were analyzed directly by spectrophotometric analyses, using
the triglyceride quantification kit (BioVision, Mountain View, CA), according to
the manufacturer’s instructions. Total protein levels were quantified with DC
protein assay (BioRad). Triglyceride levels were expressed per milligram of
protein.
Fluorescence Microscopy
Sixty percent to 70% confluent cells were fixed for 15min with 4% paraformal-
dehyde and 4% sucrose in PBS. After two PBS washes, cells were permeabi-
lized with 0.25% Triton_ X-100 (Sigma) in PBS for 5 min and blocked with 10%
bovine serum albumin (BSA) in PBS for 30 min at 37C. Immunofluorescence
staining was performed by incubation with the following primary antibodies in
3% BSA/PBS: mouse monoclonal anti-NS5A (1:1,000; Chemicon Interna-
tional, Billerica, MA), rabbit monoclonal anti-FASN (1:50, Santa Cruz Biotech-
nology), and mouse monoclonal anti-dsRNA (1:3,000; Scicons, cat.no.
10010200). Consequently, the samples were washed three times with PBS
for 5min and incubated for 1 hr at 37C in 3%BSA/PBS containing the respec-
tive secondary antibody: Rhodamine Red-X donkey anti-rabbit (1:1,000); or
Cy2 donkey anti-mouse (1:1,000) (Jackson ImmunoResearch). Fluorescence
images were collected using an Axiovert 200M inverted microscope (Carl
Zeiss, Thornwood, NY) equipped with the Axiovision 3.1 software. The cells
were then photographed with an AxioCam connected to the inverted
microscope.570–582, April 18, 2013 ª2013 Elsevier Ltd All rights reserved 579
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for 4 hr in growth medium at 37C and 5% CO2. Medium containing 1%
DMSO was used as a negative control. The cells were then washed twice
with PBS, and fixed with 4%paraformaldehyde in PBS for 15min at room tem-
perature, washed with PBS (2 3 5 min with gentle agitation), and permeabi-
lized with 0.1% Triton X-100 in PBS for 15 min at room temperature, and
washed with PBS (2 3 5 min with gentle agitation). The cells were blocked
with 3% BSA in PBS for 30 min at room temperature, and washed with PBS
(2 3 5 min with gentle agitation). The cells were then treated with a freshly
premixed click chemistry reaction solution of rhodamine azide (10 mM final
concentration from a 10 mM stock solution in DMSO), TCEP (1 mM final con-
centration from a 50 mM freshly prepared stock solution in deionized water),
TBTA (100 mM final concentration from a 10 mM stock solution in DMSO),
and CuSO4 (1 mM final concentration from a 100 mM freshly prepared stock
solution in deionized water), in PBS for 1 hr at room temperature. The cells
were washed with PBS (1 3 5 min with gentle agitation) and cold methanol
(1 3 5 min with gentle agitation), followed by 1% Tween-20 and 0.5 mM of
EDTA in PBS (3 3 2 min with gentle agitation), and with PBS (2 3 5 min with
gentle agitation). For colocalization of FASN and HCV RC, indirect immunoflu-
orescent cytochemical staining was carried out with either anti-NS5A or
anti-dsRNA as described previously.
Colocalization analyses were performed using colocalization analysis
plug-in of ImageJ and the Mander’s and Pearson’s coefficient were calculated
by Mander’s calculator. The results are shown as the mean of five different
image sets per sample, subsequent to background correction and exclusion
of zero-zero pixels.
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